“I don’t want to shock anyone but there may be a need for people to get an additional booster in the fall, along with a more general booster campaign if that takes place, because we may need to shift over to a different variant coverage,” Dr. Peter Marks, head of the FDA center that regulates vaccines, told reporters on a call on March 29.
Moderna and Pfizer are testing vaccine formulations that specifically target Omicron.
“It may be that a decision is made that rather than what we currently have, the vaccines we currently have—which are called vaccines against the prototype virus—that we will move to a vaccine that is either against one of the variants—whether it’s Omicron, Beta, or Delta, or something else, I can’t say right now that’s for discussion—or whether it’s some mix of different ones,” Marks said. “But it’s possible that people will need to get another vaccine.”
The FDA authorized the outdated boosters because regulators felt doing so could save lives and because it will likely take several months to discern whether an Omicron-specific booster works, he added.
“And it’s not actually clear yet what the optimal booster should be,” Marks said.
Some experts have raised concerns about repeatedly injecting people with COVID-19 vaccines. The worries stem in part from the main vaccines being built on a technology, messenger RNA, that had never been cleared for use before the pandemic, with others noting that other vaccines provide sufficient protection through shots administered annually, or at less frequent intervals.
“This is the risk associated with this strategy of reboosting,” he told The Epoch Times.
Presented with Marks’ remarks, Malone said they were “pure speculation and unfounded.”
“That’s a forward looking statement. There’s no scientific basis for evaluating it. And it’s inappropriate for the FDA to be speculating like that, in my opinion,” he said.